|
Project Title:
Long-Term Outcomes of NO for Ventilated Premature Babies
Funding Agency:
National Institutes of Health
Total Project Period:
Dec 15, 2002 – Nov 30, 2007
Principal Investigator:
Derek Angus, MD
Co-Investigator(s):
Robert Watson; Gilles Clermont; Mark Roberts; Judith Lave; Lisa Weissfeld; John
Kinsella; Steve Abman; Gary Cutter; Walter-Linde Zwirble; Forrest C. Bennett.
Project Summary:
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that improves pulmonary gas exchange and may have lung-specific anti-inflammatory properties. INO improves short-term outcomes in term neonates with hypoxemic respiratory failure and has been approved for use in these patients. A new NHLBI-funded randomized controlled trial (CLD) at 36 weeks post-conceptional age in pre-term newborns with respiratory failure.
Prematurity-associated respiratory failure has a different etiology from respiratory failure in term infants and has a wide array of long-term consequences that my be affected by iNO yet may not be captured under existing study design. We therefore propose to extend and enhance the follow-up of the NHLBI iNO RCT.
Our findings will aid clinicians, families and policymakers and immediately affect care of critically ill infants. By combining with the NHLBI iNO RCT, we take advantage of an important opportunity to gather prospective long-term outcome data in a randomized fashion. Our proposal will significantly increase the return on investment in the RCT through a greater understanding of the impact of iNO therapy from a societal perspective. We will also generate contemporary data on the long-term consequences of prematurity-associated respiratory failure, thus providing a reliable estimate of the appropriate follow-up for future clinical trials in this condition and stimulating future research.
|
